Influenza Vaccine Effectiveness Against Antigenically Drifted Influenza Higher Than Expected in Hospitalized Adults: 2014-2015

Clinical Infectious Diseases

Volumn 63, Issue 8, 2016, Pages 1017-1025

  Petrie, Joshua G ^a   Ohmit, Suzanne E ^a   Cheng, Caroline K ^a   Martin, Emily T ^a   Malosh, Ryan E ^a   Lauring, Adam S ^b,c   Lamerato, Lois E ^b   Reyes, Katherine C ^d   Flannery, Brendan ^e   Ferdinands, Jill M ^e   Monto, Arnold S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Department of Microbiology and Immunology ^*  (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Henry Ford Health System Division of Infectious Diseases   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antigenic drift; Case test negative design; Hospital; Influenza A (H3N2); Influenza vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; AGED; ANTIGENICITY; ARTICLE; COMORBIDITY; FEMALE; GENETIC DRIFT; HOSPITAL PATIENT; HUMAN; INFLUENZA; INFLUENZA A (H3N2); MAJOR CLINICAL STUDY; MALE; MICHIGAN; NOSE SMEAR; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROAT CULTURE; VACCINATION; ADOLESCENT; ANTIGENIC VARIATION; CASE CONTROL STUDY; HISTORY; HOSPITALIZATION; IMMUNOLOGY; INFLUENZA A VIRUS; LENGTH OF STAY; MIDDLE AGED; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENIC VARIATION; CASE-CONTROL STUDIES; COMORBIDITY; FEMALE; HISTORY, 21ST CENTURY; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84990956891     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw432     Document Type: Article

References (41)

1. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza A (H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis 2016; 214:1010-9.
2. Pebody RG, Warbuton F, Andrews N, al E. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill 2015; 20:30013.
3. Skowronski DM, Chambers C, Sabaiduc S, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill 2015; 20:21022.
4. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
5. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
6. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
7. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015 211:1529-40.
8. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis 2016; 213:1546-56.
9. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159-67.
10. Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22.
11. Appiah GD, Blanton L, D'Mello T, et al. Influenza activity-United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015; 64:583-90.
12. D'Mello T, Brammer L, Blanton L, et al. Update: Influenza activity-United States, September 28, 2014-February 21, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:206-12.
13. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol 2012; 865:147-62.
14. Hensley SE. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. Curr Opin Virol 2014; 8:85-9.
15. Klimov AI, Garten R, Russell C, et al. WHO recommendations for the viruses to be used in the 2012 southern hemisphere influenza vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine 2012; 30:6461-71.
16. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep 2015; 12:1-6.
17. Levine M, Sheu TG, Gubareva LV, Mishin VP. Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing. J Clin Microbiol 2011; 49:1307-12.
18. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere Influenza Season. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/201402- recommendation.pdf?ua=1. Accessed 24 February 2016.
19. Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, et al. Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Euro Surveill 2015; 20:21044.
20. McNeil SA, Andrew MK, Ye L, et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill 2015; 20:21024.
21. Gilca R, Skowronski DM, Douville-Fradet M, et al. Mid-season estimates of influenza vaccine effectiveness against influenza A(H3N2) hospitalization in the elderly in Quebec, Canada, January 2015. PLoS One 2015; 10:e0132195.
22. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-56.
23. Romero-Ortuno R,Walsh CD, Lawlor BA, Kenny RA. A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE). BMC Geriatr 2010; 10:57.
24. Centers for Disease Control and Prevention. NHIS questionnaire. Available at: ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Survey-Questionnaires/NHIS/ 2014/english/qadult.pdf. Accessed 24 February 2016.
25. Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015; 64:818-25.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45:613-9.
28. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Available at: http://www.who.int/influenza/vaccines/virus/recommendations/201402- recommendation.pdf?ua=1. Accessed 24 February 2016.
29. Firth D. Bias reduction of maximum likelihood estimates. Biometrika 1993; 80:27-38.
30. Venzon DJ, Moolgavkar SH. A method for computing profile-likelihood-based confidence intervals. J R Stat Soc Ser C Appl Stat 1988; 37:87-94.
31. American Medical Association. International Classification of Diseases: ICD-9-CM. Chicago, IL: American Medical Association, 2009.
32. McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. Vaccine 2014; 32:453-7.
33. Arriola CS, Anderson EJ, Baumbach J, et al. Does influenza vaccination modify influenza disease severity? Data on older adults hospitalized with influenza during the 2012-2013 season in the United States. J Infect Dis 2015; 212:1200-8.
34. Castilla J, Godoy P, Domínguez A, et al. Influenza vaccine effectiveness in preventing outpatient, inpatient and severe cases of laboratory-confirmed influenza. Clin Infect Dis 2013; 57:167-75.
35. Casado I, Domínguez A, Toledo D, et al. Effect of influenza vaccination on the prognosis of hospitalized influenza patients. Expert Rev Vaccines 2016; 15:425-32.
36. Talbot HK, Zhu Y, Chen Q, et al. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis 2013; 56:1774-7.
37. Talbot HK, Griffin MR, Chen Q, et al. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011; 203:500-8.
38. Feng S, Cowling BJ, Sullivan SG. Influenza vaccine effectiveness by test-negative design-comparison of inpatient and outpatient settings. Vaccine 2016; 34:1672-9.
39. Foppa IM, Ferdinands JM, Chaves SS, et al. The case test-negative design for studies of the effectiveness of influenza vaccination in inpatient settings. Int J Epidemiol 2016; doi:10.1093/ije/dyw022.
40. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006; 35:345-52.
41. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133-8.